Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.

Polyglutamine (polyQ) disorders are a group of nine neurodegenerative diseases that share a common genetic cause, which is an expansion of CAG repeats in the coding region of the causative genes that are otherwise unrelated. The trinucleotide expansion encodes for an expanded polyQ tract in the respective proteins, resulting in toxic gain-of-function and eventually in neurodegeneration. Currently, no disease-modifying therapies are available for this group of disorders. Nevertheless, given their monogenic nature, polyQ disorders are ideal candidates for therapies that target specifically the gene transcripts. Antisense oligonucleotides (ASOs) have been under intense investigation over recent years as gene silencing tools. ASOs are small synthetic single-stranded chains of nucleic acids that target specific RNA transcripts through several mechanisms. ASOs can reduce the levels of mutant proteins by breaking down the targeted transcript, inhibit mRNA translation or alter the maturation of the pre-mRNA via splicing correction. Over the years, chemical optimization of ASO molecules has allowed significant improvement of their pharmacological properties, which has in turn made this class of therapeutics a very promising strategy to treat a variety of neurodegenerative diseases. Indeed, preclinical and clinical strategies have been developed in recent years for some polyQ disorders using ASO therapeutics. The success of ASOs in several animal models, as well as encouraging results in the clinic for Huntington's disease, points toward a promising future regarding the application of ASO-based therapies for polyQ disorders in humans, offering new opportunities to address unmet medical needs for this class of disorders. This review aims to present a brief overview of key chemical modifications, mechanisms of action and routes of administration that have been described for ASO-based therapies. Moreover, it presents a review of the most recent and relevant preclinical and clinical trials that have tested ASO therapeutics in polyQ disorders.

[1]  M. DiFiglia,et al.  A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system , 2019, Nature Biotechnology.

[2]  N. Datson,et al.  Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide , 2019, Molecular therapy. Nucleic acids.

[3]  R. Barker,et al.  Targeting Huntingtin Expression in Patients with Huntington's Disease. , 2019, The New England journal of medicine.

[4]  R. Albin,et al.  Polyglutamine Repeats in Neurodegenerative Diseases. , 2019, Annual review of pathology.

[5]  W. V. van Roon-Mom,et al.  Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias , 2019, Neurotherapeutics.

[6]  H. Zoghbi,et al.  Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles. , 2018, JCI insight.

[7]  A. L. La Spada,et al.  Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7 , 2018, Science Translational Medicine.

[8]  Lisa M Anderson,et al.  Huntingtin suppression restores cognitive function in a mouse model of Huntington’s disease , 2018, Science Translational Medicine.

[9]  K. Yagi,et al.  Angubindin‐1 opens the blood–brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[10]  T. Ashizawa,et al.  Intravenously Administered Novel Liposomes, DCL64, Deliver Oligonucleotides to Cerebellar Purkinje Cells , 2018, The Cerebellum.

[11]  H. Paulson,et al.  Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice , 2018, Annals of neurology.

[12]  R. Scannevin.  Therapeutic strategies for targeting neurodegenerative protein misfolding disorders. , 2018, Current opinion in chemical biology.

[13]  S. Crooke,et al.  Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides , 2018, Nucleic acids research.

[14]  T. Singer,et al.  A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides , 2017, Molecular therapy. Nucleic acids.

[15]  M. Lindow,et al.  RNase H sequence preferences influence antisense oligonucleotide efficiency , 2017, Nucleic acids research.

[16]  L. Pereira de Almeida,et al.  Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases. , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Naoki Iwamoto,et al.  Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides , 2017, Nature Biotechnology.

[18]  Harry T. Orr,et al.  Polyglutamine spinocerebellar ataxias — from genes to potential treatments , 2017, Nature Reviews Neuroscience.

[19]  H. van Attikum,et al.  Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice , 2017, Molecular therapy. Nucleic acids.

[20]  S. Crooke,et al.  RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  K. Schoch,et al.  Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases , 2017, Neuron.

[22]  Daniel R. Scoles,et al.  Antisense oligonucleotide therapy for spinocerebellar ataxia type 2 , 2017, Nature.

[23]  H. Paulson,et al.  Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models , 2017, Molecular therapy. Nucleic acids.

[24]  David A. Knowles,et al.  Therapeutic reduction of ataxin 2 extends lifespan and reduces pathology in TDP-43 mice , 2017, Nature.

[25]  Stanley T Crooke,et al.  Cellular uptake and trafficking of antisense oligonucleotides , 2017, Nature Biotechnology.

[26]  N. Datson,et al.  The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain , 2017, PloS one.

[27]  Y. Temel,et al.  Distribution and Penetration of Intracerebroventricularly Administered 2'OMePS Oligonucleotide in the Mouse Brain. , 2017, Nucleic Acid Therapeutics.

[28]  Y. Temel,et al.  In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[29]  X. Estivill,et al.  Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels. , 2016, The Journal of clinical investigation.

[30]  H. van Attikum,et al.  Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3 , 2016, Scientific Reports.

[31]  M. Bowerman,et al.  Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy , 2016, Proceedings of the National Academy of Sciences.

[32]  T. Kasuya,et al.  Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides , 2016, Scientific Reports.

[33]  S. Linnarsson,et al.  Characterization and target genes of nine human PRD-like homeobox domain genes expressed exclusively in early embryos , 2016, Scientific Reports.

[34]  S. Crooke,et al.  Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides , 2016, Nucleic acids research.

[35]  S. Pulst.  Degenerative ataxias, from genes to therapies , 2016, Neurology.

[36]  Mallory A. Havens,et al.  Splice-switching antisense oligonucleotides as therapeutic drugs , 2016, Nucleic acids research.

[37]  R. Juliano,et al.  The delivery of therapeutic oligonucleotides , 2016, Nucleic acids research.

[38]  Jacqueline Montes,et al.  Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy , 2016, Neurology.

[39]  S. Crooke,et al.  Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2′-modifications and enhances antisense activity , 2016, Nucleic acids research.

[40]  S. Humbert,et al.  The Biology of Huntingtin , 2016, Neuron.

[41]  A. J. Donner,et al.  Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver , 2016, Nucleic acids research.

[42]  S. Crooke,et al.  The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA , 2015, Nucleic acids research.

[43]  G. Sobue,et al.  Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. , 2015, Human molecular genetics.

[44]  R. Juliano,et al.  Cellular uptake and intracellular trafficking of oligonucleotides. , 2015, Advanced drug delivery reviews.

[45]  C. Bennett,et al.  Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. , 2015, Advanced drug delivery reviews.

[46]  P. Sorensen,et al.  Direct intracerebral delivery of a miR-33 antisense oligonucelotide into mouse brain increases brain ABCA1 expression , 2015, Neuroscience Letters.

[47]  Lance T. Pflieger,et al.  Ataxin-2 Regulates RGS8 Translation in a New BAC-SCA2 Transgenic Mouse Model , 2015, PLoS genetics.

[48]  S. Freier,et al.  In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  R. Margolis,et al.  Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. , 2014, Human molecular genetics.

[50]  S. Freier,et al.  Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients , 2014, PloS one.

[51]  J. Cooper,et al.  Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice , 2014, Movement disorders : official journal of the Movement Disorder Society.

[52]  Y. Hua,et al.  Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[53]  S. Crooke,et al.  TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells , 2014, Nucleic acids research.

[54]  L. Pereira de Almeida,et al.  Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease. , 2014, Human molecular genetics.

[55]  Shuling Guo,et al.  Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. , 2014, Cell reports.

[56]  T. Dalkara,et al.  An aquaporin 4 antisense oligonucleotide loaded, brain targeted nanoparticulate system design. , 2014, Die Pharmazie.

[57]  F. Rigo,et al.  Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides , 2014, Nucleic acids research.

[58]  B. Davidson,et al.  Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[59]  G. van Ommen,et al.  Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification. , 2014, Nucleic acid therapeutics.

[60]  G. Lederkremer,et al.  Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress , 2013, Nature Communications.

[61]  G. V. Ommen,et al.  Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon , 2013, Neurobiology of Disease.

[62]  M. Hayden,et al.  Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS , 2013, Nucleic acids research.

[63]  Sarah L. DeVos,et al.  Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA , 2013, Neurotherapeutics.

[64]  A. Pestronk,et al.  An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study , 2013, The Lancet Neurology.

[65]  E. Wanker,et al.  Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1–PP2A protein complex , 2013, Nature Communications.

[66]  M. Hayden,et al.  Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. , 2012, Trends in molecular medicine.

[67]  S. Pulst,et al.  Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2 , 2012, Human molecular genetics.

[68]  M. Wolfe,et al.  Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing , 2012, Nucleic acids research.

[69]  L. Shihabuddin,et al.  Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis , 2012, Neuron.

[70]  Harry T. Orr,et al.  Cell biology of spinocerebellar ataxia , 2012, The Journal of cell biology.

[71]  X. Estivill,et al.  A Pathogenic Mechanism in Huntington's Disease Involves Small CAG-Repeated RNAs with Neurotoxic Activity , 2012, PLoS genetics.

[72]  E. Junn,et al.  MicroRNAs in neurodegenerative diseases and their therapeutic potential. , 2012, Pharmacology & therapeutics.

[73]  J. Stenvang,et al.  Inhibition of microRNA function by antimiR oligonucleotides , 2012, Silence.

[74]  B. Davidson,et al.  Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[75]  S. Freier,et al.  Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[76]  Carlos A. Matos,et al.  Polyglutamine diseases: The special case of ataxin-3 and Machado–Joseph disease , 2011, Progress in Neurobiology.

[77]  H. Paulson,et al.  Early Changes in Cerebellar Physiology Accompany Motor Dysfunction in the Polyglutamine Disease Spinocerebellar Ataxia Type 3 , 2011, The Journal of Neuroscience.

[78]  G. van Ommen,et al.  Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide , 2011, PloS one.

[79]  M. Q. Kemp,et al.  Impaired motoneuronal retrograde transport in two models of SBMA implicates two sites of androgen action. , 2011, Human molecular genetics.

[80]  P. Iversen,et al.  Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. , 2011, Human molecular genetics.

[81]  K. Sobczak,et al.  CAG repeats mimic CUG repeats in the misregulation of alternative splicing , 2011, Nucleic acids research.

[82]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[83]  Y. Hua,et al.  Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy , 2011, Science Translational Medicine.

[84]  M. Manoharan,et al.  Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes , 2011, Nucleic acids research.

[85]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[86]  John Q. Trojanowski,et al.  Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS , 2010, Nature.

[87]  Y. Hua,et al.  Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. , 2010, Genes & development.

[88]  Elena Cattaneo,et al.  Molecular mechanisms and potential therapeutical targets in Huntington's disease. , 2010, Physiological reviews.

[89]  D. Golenbock,et al.  Alternating 2'-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. , 2010, Immunobiology.

[90]  Xiaoyuan Chen,et al.  Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor , 2010, Nucleic acids research.

[91]  N. Déglon,et al.  Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? , 2010, Human molecular genetics.

[92]  M. Hayden,et al.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. , 2010, Human molecular genetics.

[93]  J. Taylor,et al.  Repeat expansion disease: progress and puzzles in disease pathogenesis , 2010, Nature Reviews Genetics.

[94]  S. Finkbeiner,et al.  Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease* , 2010, The Journal of Biological Chemistry.

[95]  C. Bennett,et al.  RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. , 2010, Annual review of pharmacology and toxicology.

[96]  R. Geary,et al.  Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. , 2009, Biochemical pharmacology.

[97]  Alcino J. Silva,et al.  Dissociated Fear and Spatial Learning in Mice with Deficiency of Ataxin-2 , 2009, PloS one.

[98]  I. Martins,et al.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[99]  D. Corey,et al.  Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs , 2009, Nature Biotechnology.

[100]  Marion Jurk,et al.  Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. , 2009, International immunology.

[101]  R. Cole,et al.  Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells* , 2009, Journal of Biological Chemistry.

[102]  D. Corey,et al.  Inhibiting Expression of Mutant Huntingtin and Ataxin-3 by Targeting Expanded CAG Repeat RNAs , 2009, Nature biotechnology.

[103]  Harry T Orr,et al.  Pathogenic Mechanisms of a Polyglutamine-mediated Neurodegenerative Disease, Spinocerebellar Ataxia Type 1* , 2009, Journal of Biological Chemistry.

[104]  R. Crouch,et al.  Ribonuclease H: the enzymes in eukaryotes , 2009, The FEBS journal.

[105]  D. Witchell,et al.  Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. , 2009, Journal of medicinal chemistry.

[106]  P. Iversen,et al.  Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[107]  M. Hayden,et al.  Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. , 2008, Brain : a journal of neurology.

[108]  Y. Hua,et al.  Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. , 2008, American journal of human genetics.

[109]  K. Lamborn,et al.  Neuro-oncology New Therapeutic Approach for Brain Tumors: Intranasal Delivery of Telomerase Inhibitor Grn163 , 2006 .

[110]  Xiaoyuan Chen,et al.  Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis , 2008, Nucleic acids research.

[111]  Osamu Onodera,et al.  Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. , 2008, Human molecular genetics.

[112]  S. Crooke,et al.  Human RNase H1 Discriminates between Subtle Variations in the Structure of the Heteroduplex Substrate , 2007, Molecular Pharmacology.

[113]  B. Monia,et al.  Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals , 2006, Nucleic acids research.

[114]  G. Sobue,et al.  Reversible Disruption of Dynactin 1-Mediated Retrograde Axonal Transport in Polyglutamine-Induced Motor Neuron Degeneration , 2006, The Journal of Neuroscience.

[115]  B. Monia,et al.  Antisense oligonucleotide therapy for neurodegenerative disease. , 2006, The Journal of clinical investigation.

[116]  L. Raymond,et al.  Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin , 2006, Cell.

[117]  A. Levin,et al.  Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). , 2006, Oligonucleotides.

[118]  A. Rabinowitz,et al.  Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology , 2006, Nature Medicine.

[119]  S. Murray,et al.  Spinal distribution and metabolism of 2′-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats , 2005, Neuroscience.

[120]  H. Paulson,et al.  RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia , 2004, Nature Medicine.

[121]  S. Crooke,et al.  Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs* , 2004, Journal of Biological Chemistry.

[122]  H. Hansen,et al.  Nuclease Stability of LNA Oligonucleotides and LNA-DNA Chimeras , 2003, Nucleosides, nucleotides & nucleic acids.

[123]  Jens Kurreck,et al.  Antisense technologies. Improvement through novel chemical modifications. , 2003, European journal of biochemistry.

[124]  Junying Yuan,et al.  Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders , 2003, Nature.

[125]  D. Corey,et al.  Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. , 2002, Nucleic acids research.

[126]  N. Chauhan.  Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain. , 2002, Antisense & nucleic acid drug development.

[127]  K. Fischbeck,et al.  Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. , 2002, Human molecular genetics.

[128]  K. Lindenberg,et al.  Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. , 2002, Molecular cell.

[129]  W. Banks,et al.  Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. , 2001, The Journal of pharmacology and experimental therapeutics.

[130]  S. Freier,et al.  Fully modified 2' MOE oligonucleotides redirect polyadenylation. , 2001, Nucleic acids research.

[131]  E. Lesnik,et al.  Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. , 2001, The Journal of pharmacology and experimental therapeutics.

[132]  Michael S. Levine,et al.  Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice , 2000, Nature Genetics.

[133]  T. Hökfelt,et al.  Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[134]  K. Stecker,et al.  Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. , 2000, The Journal of pharmacology and experimental therapeutics.

[135]  A. Levin.  A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. , 1999, Biochimica et biophysica acta.

[136]  J. Butler,et al.  Thermodynamic comparison of PNA/DNA and DNA/DNA hybridization reactions at ambient temperature. , 1999, Nucleic acids research.

[137]  S. Crooke,et al.  Properties of Cloned and Expressed Human RNase H1* , 1999, The Journal of Biological Chemistry.

[138]  J. Wengel.  Synthesis of 3‘-C- and 4‘-C-Branched Oligodeoxynucleotides and the Development of Locked Nucleic Acid (LNA) , 1999 .

[139]  L. Chappell,et al.  Oligonucleotide-europium complex conjugate designed to cleave the 5' cap structure of the ICAM-1 transcript potentiates antisense activity in cells. , 1999, Nucleic acids research.

[140]  F. Holsboer,et al.  Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. , 1999, Journal of psychiatric research.

[141]  L. Miraglia,et al.  Characterization of a Potent and Specific Class of Antisense Oligonucleotide Inhibitor of Human Protein Kinase C-α Expression* , 1999, The Journal of Biological Chemistry.

[142]  W. Zhang,et al.  Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS. , 1998, Brain research. Molecular brain research.

[143]  H. Zoghbi,et al.  Mice Lacking Ataxin-1 Display Learning Deficits and Decreased Hippocampal Paired-Pulse Facilitation , 1998, The Journal of Neuroscience.

[144]  Y. Agid,et al.  Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). , 1998, Human molecular genetics.

[145]  S. Freier,et al.  The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. , 1997, Nucleic acids research.

[146]  Georg Auburger,et al.  Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2 , 1996, Nature Genetics.

[147]  J. Clark,et al.  Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice. , 1996, The American journal of pathology.

[148]  Y. Agid,et al.  Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias , 1995, Nature.

[149]  D. Pfaff,et al.  Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain , 1995, Regulatory Peptides.

[150]  Virginia E. Papaioannou,et al.  Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue , 1995, Nature Genetics.

[151]  M. Hentze,et al.  Target-specific arrest of mRNA translation by antisense 2'-O-alkyloligoribonucleotides. , 1994, Nucleic acids research.

[152]  M. Nerenberg,et al.  Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. , 1994, The Journal of biological chemistry.

[153]  J. Toulmé,et al.  Characterization and subcellular localization of ribonuclease H activities from Xenopus laevis oocytes. , 1994, The Journal of biological chemistry.

[154]  V V Demidov,et al.  Stability of peptide nucleic acids in human serum and cellular extracts. , 1994, Biochemical pharmacology.

[155]  M. Egli,et al.  Stabilizing effects of the RNA 2'-substituent: crystal structure of an oligodeoxynucleotide duplex containing 2'-O-methylated adenosines. , 1994, Chemistry & biology.

[156]  S. Gryaznov,et al.  Oligodeoxyribonucleotide N3'.fwdarw.P5' Phosphoramidates: synthesis and Hybridization Properties , 1994 .

[157]  Peter E. Nielsen,et al.  PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen-bonding rules , 1993, Nature.

[158]  P. D. Cook,et al.  Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. , 1993, The Journal of biological chemistry.

[159]  Huda Y. Zoghbi,et al.  Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1 , 1993, Nature Genetics.

[160]  Y. Kagawa,et al.  The gene for Machado–Joseph disease maps to human chromosome 14q , 1993, Nature Genetics.

[161]  L. Neckers,et al.  Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[162]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[163]  M. Egholm,et al.  Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. , 1991, Science.

[164]  S. Agrawal,et al.  Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[165]  K. Fischbeck,et al.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy , 1991, Nature.

[166]  E. Wickstrom,et al.  Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. , 1990, Journal of biochemical and biophysical methods.

[167]  K. Shinozuka,et al.  Physicochemical properties of phosphorothioate oligodeoxynucleotides. , 1988, Nucleic acids research.

[168]  Carlos A. Matos,et al.  Gene Therapies for Polyglutamine Diseases. , 2018, Advances in experimental medicine and biology.

[169]  A. L. La Spada,et al.  X-Linked Spinal and Bulbar Muscular Atrophy: From Clinical Genetic Features and Molecular Pathology to Mechanisms Underlying Disease Toxicity. , 2018, Advances in experimental medicine and biology.

[170]  Y. Trottier,et al.  Molecular Mechanisms and Therapeutic Strategies in Spinocerebellar Ataxia Type 7. , 2018, Advances in experimental medicine and biology.

[171]  M. Wood,et al.  Antisense oligonucleotides: the next frontier for treatment of neurological disorders , 2018, Nature Reviews Neurology.

[172]  M. Hayden,et al.  Huntington disease , 2015, Nature Reviews Disease Primers.

[173]  W. Banks,et al.  Central and peripheral administration of antisense oligonucleotide targeting amyloid-β protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (AβPPswe) mice. , 2014, Journal of Alzheimer's disease : JAD.

[174]  M. Hayden,et al.  Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease. , 2013, Journal of Huntington's disease.

[175]  H. Paulson.  Machado-Joseph disease/spinocerebellar ataxia type 3. , 2012, Handbook of clinical neurology.

[176]  Stefan M Pulst,et al.  Spinocerebellar ataxia type 2. , 2012, Handbook of clinical neurology.

[177]  J. Jaroszewski,et al.  NMR investigations of duplex stability of phosphorothioate and phosphorodithioate DNA analogues modified in both strands. , 1996, Nucleic acids research.

[178]  D. Barofsky,et al.  Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. , 1996, Antisense & nucleic acid drug development.

[179]  Sergei M. Gr yaznov,et al.  8 Oligonucleotide N3 ′ (cid:1) P5 ′ phosphoramidates as antisense , 1996 .

[180]  Shigenobu Nakamura,et al.  CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1 , 1994, Nature Genetics.

[181]  D. L. Weeks,et al.  Pathways of degradation and mechanism of action of antisense oligonucleotides in Xenopus laevis embryos. , 1991, Antisense research and development.

[182]  J. Walder,et al.  Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma. , 1991, Antisense research and development.

[183]  R. Kole,et al.  Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. , 1991, Life sciences.

[184]  M. Stephenson,et al.  Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[185]  S. Crooke,et al.  Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages , 2022 .